Ocular Therapeutix, Inc. $OCUL Stock Purchased by Profund Advisors LLC

Profund Advisors LLC boosted its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 316.0% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 138,128 shares of the biopharmaceutical company’s stock after acquiring an additional 104,927 shares during the quarter. Profund Advisors LLC’s holdings in Ocular Therapeutix were worth $1,059,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Rockefeller Capital Management L.P. purchased a new stake in Ocular Therapeutix in the 4th quarter worth about $31,000. Integrated Wealth Concepts LLC purchased a new position in shares of Ocular Therapeutix during the second quarter valued at approximately $51,000. Sterling Capital Management LLC boosted its position in shares of Ocular Therapeutix by 401.7% during the third quarter. Sterling Capital Management LLC now owns 6,612 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 5,294 shares during the period. Root Financial Partners LLC purchased a new position in shares of Ocular Therapeutix during the third quarter valued at approximately $66,000. Finally, Trust Co. of Vermont bought a new position in shares of Ocular Therapeutix during the second quarter valued at approximately $112,000. 59.21% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Ocular Therapeutix

In other news, insider Peter Kaiser sold 9,990 shares of Ocular Therapeutix stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $7.05, for a total transaction of $70,429.50. Following the completion of the sale, the insider owned 254,388 shares of the company’s stock, valued at approximately $1,793,435.40. The trade was a 3.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Jeffrey Heier sold 10,869 shares of the business’s stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $7.05, for a total value of $76,626.45. Following the completion of the sale, the insider owned 307,457 shares of the company’s stock, valued at $2,167,571.85. The trade was a 3.41% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 62,720 shares of company stock valued at $556,247. 3.10% of the stock is owned by insiders.

Analysts Set New Price Targets

OCUL has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating on shares of Ocular Therapeutix in a report on Tuesday, October 20th. Royal Bank Of Canada reissued an “outperform” rating on shares of Ocular Therapeutix in a research note on Tuesday, September 29th. Chardan Capital restated a “buy” rating and set a $23.00 price objective on shares of Ocular Therapeutix in a report on Friday, October 2nd. Zacks Research raised Ocular Therapeutix from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Finally, Wall Street Zen upgraded Ocular Therapeutix from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Ocular Therapeutix presently has an average rating of “Moderate Buy” and an average price target of $23.33.

Ocular Therapeutix Stock Performance

Shares of OCUL opened at $6.82 on Wednesday. Ocular Therapeutix, Inc. has a 1-year low of $6.00 and a 1-year high of $16.44. The company has a 50-day moving average of $8.65 and a 200 day moving average of $9.09. The company has a current ratio of 13.10, a quick ratio of 13.03 and a debt-to-equity ratio of 0.14.

Ocular Therapeutix (NASDAQ:OCUL) last issued its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.05. The business had revenue of $13.47 million for the quarter, compared to the consensus estimate of $13.20 million. Ocular Therapeutix had a negative net margin of 579.10% and a negative return on equity of 59.89%. The company’s revenue for the quarter was down .1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.39) EPS. As a group, research analysts anticipate that Ocular Therapeutix, Inc. will post -1.47 earnings per share for the current fiscal year.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc (NASDAQ:OCUL) is a biopharmaceutical company focused on developing and commercializing therapies for diseases and conditions affecting the eye. The company uses its proprietary hydrogel-based drug-delivery technology to provide sustained or controlled release of medicines in ophthalmic applications.

Its commercial products include Dextenza, a dexamethasone ophthalmic insert used to treat ocular inflammation and itching following ophthalmic surgery, and Yutiq, a fluocinolone acetonide intravitreal implant indicated for the treatment of chronic noninfectious posterior uveitis.